ISSN:
1432-1041
Keywords:
glibenclamide
;
acarbose
;
kinetics
;
alpha-glucosidase inhibitor
;
blood glucose control
;
plasma insulin
;
Type 2 diabetes
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary A single dose of glibenclamide 5 mg was administered to six Type 2 diabetics, randomly treated for 7 days either with acarbose (3×100 mg daily) or with placebo. The serum concentration of the drug was measured for 10 h. Peak concentrations, times-to-peak concentration, elimination half-lives and the extent of bioavailability of the drug were not significantly modified by acarbose. The combined administration of glibenclamide and acarbose resulted in a modest improvement in the blood glucose profile after breakfast and lunch, together with a significant diminution in plasma insulin. Thus, acarbose appears a useful additional treatment for Type 2 diabetics already receiving sulphonylurea derivatives.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00544051
Permalink
